MetaVia Inc. announced promising Phase 1 results for DA-1726, a dual GLP1R/GCGR agonist, showing up to 9.1% mean body weight reduction by Day 54 without plateau, alongside reduced waist circumference and BMI. Preclinical studies revealed that vanoglipel combined with resmetirom or metformin produced synergistic benefits in liver health, glycemic control, and weight loss in models of metabolic diseases. These findings support DA-1726 as a differentiated obesity therapy and vanoglipel as a versatile candidate for combination treatments in metabolic dysfunction-associated steatohepatitis (MASH) and type 2 diabetes. MetaVia plans to continue higher-dose evaluations with results expected by Q4 2026.
The US government is actively negotiating to take equity stakes in AI companies like OpenAI and Anthropic ahead of their planned IPOs, following a precedent set by its investment in Intel. This move aims to give the public a share in AI-driven growth...
Trulieve Cannabis Corp. made history by becoming the first U.S. cannabis company to list on the New York Stock Exchange under the ticker TRLV. This milestone was enabled by the Trump administration's reclassification of cannabis to Schedule III for m...
West Fraser Timber Co. Ltd. announced a quarterly dividend of US$0.32 per share on its Common and Class B Common shares. The dividend will be paid on July 13, 2026, to shareholders of record as of June 25, 2026. Shareholders have the option to receiv...
BIO-key International, a leader in biometric authentication, received a Nasdaq notice for failing to file its quarterly 10-Q report on time for Q1 2026. Nasdaq's notice indicates the company's compliance with listing rules is under review, and a hear...
Nyxoah SA has issued 55,232,558 new ordinary shares as part of a previously announced public offering, increasing the total number of shares with voting rights to 99,926,284. This move follows a private placement to qualified investors outside the U....
